Xenon Pharmaceuticals Inc. has dropped its lead internal candidate, XEN801, after it failed to improve moderate to severe acne in a Phase II trial. The development calls into questions this novel approach to the disease and the company's share price dropped by nearly 53% to close at $4.65 on NASDAQ on Mar. 24 when the results were announced.
Xenon Down On Novel Acne Treatment Failure
Xenon Pharmaceuticals' attempts to treat acne with a SCD-1 inhibitor have met with failure at the Phase II stage, casting doubt on the therapeutic strategy and wiping more than 50% of the company's share price.
